Can Amylin Weight-Loss Drugs Compete in a World of GLP-1s?

Why It Matters

Amylin‑based therapies could address the safety and efficacy gaps of GLP‑1s, reshaping market share and expanding treatment options for obesity and diabetes patients.

Key Takeaways

• CagriSema cut weight 23% vs tirzepatide 25.5%.
• Amylin analogs show better muscle preservation than GLP‑1s.
• Side‑effect profile of amylin drugs markedly lower.
• Novo, Lilly, Roche, AbbVie all advancing amylin pipelines.
• Weight‑loss market projected $150 B by 2035.

Pulse Analysis

The past decade has seen GLP‑1 receptor agonists such as semaglutide and tirzepatide become blockbuster obesity treatments, generating combined sales in the tens of billions of dollars. Yet clinicians and patients increasingly cite gastrointestinal distress, high cost, and significant lean‑muscle loss as barriers to long‑term adherence. Analysts estimate that more than 40% of users discontinue GLP‑1 therapy within two years, prompting pharmaceutical giants to diversify their pipelines and investors to seek alternatives that can sustain weight loss without compromising metabolic health.

Enter amylin analogs, a class of peptides that act on distinct brain receptors to promote satiety while preserving muscle mass. Novo Nordisk’s CagriSema—a hybrid of semaglutide and the long‑acting amylin analog cagrilintide—delivered a 23% reduction in body weight in Phase 3 trials, only slightly below Lilly’s tirzepatide benchmark. Meanwhile, Lilly’s eloralintide achieved up to 20% weight loss in Phase 2, and Roche’s petrelintide showed a 10% reduction with minimal gastrointestinal events. Across the board, these molecules report fewer nausea and vomiting incidents, and early data suggest they may mitigate the lean‑mass loss that plagues GLP‑1s, positioning them as attractive combination partners or stand‑alone options.

The strategic implications are profound. With the obesity‑treatment market projected to swell to $150 billion by 2035, companies are racing to secure first‑to‑market advantages. Amylin‑focused firms such as Alveus Therapeutics are raising capital to accelerate preclinical programs, while legacy players like Novo and Lilly are integrating amylin components into existing GLP‑1 platforms. If these agents can deliver comparable efficacy with superior tolerability, they could erode the dominance of current GLP‑1 giants, reshape prescribing habits, and open new revenue streams for investors willing to back the next wave of metabolic medicines.